TAVR is a $5b business in the next 5 years. We are entering it cheaply with our state of the art valve material, proven engineers and a willingness from WP to partner at an early stage. I only wish he might do the same with the vaccine product.
TAVR was initially use for the very elderly unfit for bypass patient. The age is now coming down and the future will involve this procedure as routine. It should be exciting for AHZ.
Admedus dominating in Europe., page-54
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.20 |
Change
-0.550(3.10%) |
Mkt cap ! $330.6M | |||
| Open | High | Low | Value | Volume |
| $17.75 | $17.75 | $16.88 | $199.1K | 11.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $17.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.24 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |